Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 538

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 538
---
 Vaccine Licenses, which was included in the due to research and development partner amounts on the balance sheets. As of December 31, 2022, advances for research and development for the aggregate CAR-T Products and Vaccine Licenses were $1.7 million and were included in advances for research and development in the balance sheets. During 2022, the Company incurred additional short-term debt to TDT of $0.9 million for unpaid annual fees. In May 2022, the Company repaid all outstanding debt and related interest of $3.7 million, comprised of short-term debt of $3.3 million and related accrued interest of $0.4 million, to TDT.

CD-47 License

In October 2022, the Company was assigned a license and development agreement, as amended, with InnoBation (the “CD 47 License”), whereby, effective March 31, 2023, the Company received an exclusive

<div align='center'>F-80</div>

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO FINANCIAL STATEMENTSDECEMBER 31, 2023 AND 2022
license to develop and commercialize products for the CD 47 immune checkpoint inhibitor to treat solid cancers, and companion diagnostics used to monitor treatment with CD 47 products (collectively, “CD 47 Products”), from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company, in exchange for 78,555,554 of the Company’s Class A member units. The license was recorded at Valetudo’s costs basis of zero, and the Company recorded $0.8 million class A membership interest with an offset to additional paid-in capital on the balance sheet. The Company is obligated to pay all development costs for CD 47 Products. The Company has not paid and does not owe any license fees, management fees, developmental or regulatory milestone payments or royalty payments under the CD 47 License to date.

#### Note 4. Related Parties

#### Related Party Debt
Feelux Bonds

On September 15, 2018, the Company issued $10.0 million bonds to Feelux Co., Ltd., the parent company of Car-Tcellkor, Inc. (“Car-Tcellkor), the only holder of Class A member units (the “Feelux Bonds”). The bonds bear interest at 1% per annum, compounded annually, and were due on October 30,